UNSPSC 51314308: Chlorpheniramine/dextromethorphan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE507. This VA Drug Class (RE507) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE.

UNSPSC 51314308 Chlorpheniramine/dextromethorphan is a Commodity code that captures state and local procurement of branded and generic pharmaceutical products, including antihistamines, cough suppressants, and related over-the-counter and prescription medications. State and local governments buy these products primarily through standing cooperative purchasing agreements and periodic competitive solicitations that establish supply contracts with authorized pharmaceutical wholesalers and manufacturers. The buying bodies include state health and human services agencies, county health departments, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Recent solicitations emphasize compliance with Drug Supply Chain Security Act (DSCSA) requirements, Current Good Manufacturing Practice (cGMP) certifications, and pricing flexibility through multiple pricing models such as net pricing formats and wholesale acquisition cost (WAC)-minus structures.

Activity under this code concentrates in the South and Upper Midwest, with recent opportunities in Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with responses due July 26, 2023 and a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with responses due March 26, 2026, requiring suppliers to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. MMCAP evaluates proposals weighted heavily on price competitiveness (75 percent) and requires a 3 percent administrative fee plus performance penalties ranging from $200 to $1,500 per violation.